Inotiv posted first-quarter fiscal 2026 revenue of $120.9 million, up 0.8% year over year, as double‑digit growth in Discovery...

At the 2026 SCOPE Summit, Scott Megaffin, CEO of Adiso Therapeutics, detailed a transition from the economic ebb of...

Veru plans to initiate a 200-patient Phase 2b study of enobosarm as an add-on to GLP-1 receptor agonists in...

Denali Therapeutics unveiled new data across its lysosomal storage disorder portfolio and confirmed commercial readiness ahead of an April...

Ocular Therapeutix will unveil 52-week topline data from SOL-1, its Phase 3 superiority trial of the intravitreal axitinib hydrogel...

Tiziana Life Sciences’ intranasal foralumab has cleared an important credibility hurdle with the peer-reviewed publication of its open-label study...

Ascendis Pharma will report full-year 2025 results and host a business update on February 11, 2026, after the U.S....

HighLife has secured CE Mark approval for its transfemoral Transcatheter Mitral Valve Replacement system, enabling initial commercial availability across...

NMD Pharma reported topline Phase 2a results for ignaseclant in Charcot‑Marie‑Tooth disease (CMT) showing the study did not meet...

Ascendis Pharma will report full-year 2025 financials and deliver a business update on February 11, 2026, after U.S. market...